The results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone ...
Morning Overview on MSN
Seven years on, most lung cancer patients on one drug had no progression
More than half of patients with advanced ALK-positive lung cancer who started on lorlatinib seven years ago still have not ...
Sunvozertinib lung cancer treatment hit a milestone as AstraZeneca paid $600M upfront for Zegfrovy, the first oral pill to ...
The second clinical case presents a patient with ROS1 fusion-positive advanced NSCLC who achieved partial response on ...
Lung cancer (LC) is a major global health issue, with high mortality rates and limited therapeutic options. It is primarily categorized into non-small cell lung cancer (NSCLC) and small cell lung ...
Too often when patients hear the words lung cancer, they automatically assume it’s a devastating diagnosis with little reason ...
When lung cancer treatment stops working, what happens next? New research reveals the answer may depend on how the cancer grows. Medical researchers at Flinders University have uncovered an important ...
Survival in the transplant group was also similar to a cohort of non-cancer patients who underwent lung transplantation for ...
This fact sheet explains how lung cancer is staged, and what each stage means. Lung cancer staging can be complex, but this fact sheet is intended for patient education. Our easy-to-read fact sheets ...
Lung cancer remains the leading cause of cancer deaths in the United States and older adults are at higher risk. But only ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results